X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (76) 76
female (66) 66
index medicus (63) 63
postmenopausal women (61) 61
oncology (54) 54
receiving adjuvant letrozole (50) 50
breast neoplasms - drug therapy (48) 48
breast cancer (45) 45
zoledronic acid (43) 43
tamoxifen (31) 31
bone density conservation agents - therapeutic use (29) 29
diphosphonates - therapeutic use (27) 27
cancer (23) 23
care and treatment (23) 23
middle aged (23) 23
osteoporosis (23) 23
aromatase inhibitors (22) 22
breast neoplasms - pathology (22) 22
aged (19) 19
aromatase inhibitors - therapeutic use (18) 18
early breast-cancer (18) 18
follow-up (18) 18
risk factors (18) 18
antineoplastic agents, hormonal - therapeutic use (17) 17
bone density - drug effects (16) 16
endocrine therapy (16) 16
health aspects (16) 16
medicine & public health (16) 16
aromatase inhibitors - adverse effects (15) 15
bisphosphonates (15) 15
therapy (15) 15
fractures (14) 14
imidazoles - therapeutic use (14) 14
metastasis (14) 14
tamoxifen - therapeutic use (14) 14
treatment outcome (14) 14
aromatase inhibitor (13) 13
bone density (13) 13
mineral density (13) 13
bone neoplasms - secondary (12) 12
bone-mineral density (12) 12
bones (12) 12
double-blind (12) 12
drug therapy (12) 12
randomized controlled-trial (12) 12
chemotherapy, adjuvant (11) 11
denosumab (11) 11
fracture risk (11) 11
hematology, oncology and palliative medicine (11) 11
prevention (11) 11
women (11) 11
adult (10) 10
anastrozole (10) 10
antineoplastic agents - therapeutic use (10) 10
breast neoplasms - genetics (10) 10
density (10) 10
obstetrics & gynecology (10) 10
plus zoledronic acid (10) 10
premenopausal women (10) 10
randomized-trial (10) 10
aged, 80 and over (9) 9
antineoplastic agents - adverse effects (9) 9
breast neoplasms - complications (9) 9
cancer patients (9) 9
chemotherapy (9) 9
complications and side effects (9) 9
endocrinology & metabolism (9) 9
bone loss (8) 8
cytochrome p-450 cyp2d6 - genetics (8) 8
fractures, bone - prevention & control (8) 8
male (8) 8
menopause (8) 8
postmenopause (8) 8
receiving adjuvant tamoxifen (8) 8
research (8) 8
survival (8) 8
bisphosphonate (7) 7
bone density conservation agents - administration & dosage (7) 7
breast neoplasms - mortality (7) 7
breast-cancer (7) 7
cyp2d6 (7) 7
diphosphonates - administration & dosage (7) 7
disease-free survival (7) 7
estrogen (7) 7
fractures, bone - etiology (7) 7
internal medicine (7) 7
pharmacology & pharmacy (7) 7
phosphonates (7) 7
placebo-controlled trial (7) 7
randomized controlled trials as topic (7) 7
receiving adjuvant chemotherapy (7) 7
skeletal complications (7) 7
adjuvant treatment (6) 6
article (6) 6
bone mineral density (6) 6
bone neoplasms - drug therapy (6) 6
bone neoplasms - prevention & control (6) 6
breast neoplasms - metabolism (6) 6
breast neoplasms - therapy (6) 6
breast-cancer patients (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 5, pp. 1192 - 1201
BACKGROUND: Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures.... 
breast neoplasm | aromatase inhibitors | postmenopause | zoledronic acid | bone resorption | RECEIVING ADJUVANT LETROZOLE | BONE-MINERAL DENSITY | TAMOXIFEN | DOXORUBICIN | FOLLOW-UP | ANASTROZOLE | THERAPY | ONCOLOGY | EARLY BREAST-CANCER | POSTMENOPAUSAL WOMEN | PLUS ZOLEDRONIC ACID
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women... 
RECEIVING ADJUVANT LETROZOLE | MULTIPLE-MYELOMA | OVARIAN ABLATION | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | DELTA-T-CELLS | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2010, Volume 28, Issue 16, pp. 2705 - 2711
Purpose Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal... 
RECEIVING ADJUVANT LETROZOLE | ZOLEDRONIC ACID | WOMEN | BONE-MINERAL DENSITY | ONCOLOGY | TAMOXIFEN | ENDOCRINE THERAPY | FOLLOW-UP | SAFETY PROFILES | AROMATASE INHIBITORS | ANASTROZOLE | Immunohistochemistry | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Premenopause - drug effects | Neoplasm Invasiveness - pathology | Injections, Subcutaneous | Statistics, Nonparametric | Adult | Female | Goserelin - adverse effects | Postmenopause - physiology | Goserelin - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Probability | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Bone Density - drug effects | Maximum Tolerated Dose | Breast Neoplasms - pathology | Premenopause - physiology | Survival Analysis | Breast Neoplasms - mortality | Aged | Biopsy, Needle | Neoplasm Staging | Nitriles - adverse effects
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 02/2011, Volume 96, Issue 2, pp. 308 - 319
Endocrine therapies for breast cancer alter bone density, dynamic bone markers, and fracture rates, problems often requiring therapeutic intervention. Context:... 
RECEIVING ADJUVANT LETROZOLE | RANDOMIZED CONTROLLED TRIAL | MINERAL DENSITY | ESTROGEN-RECEPTOR-ALPHA | ENDOCRINOLOGY & METABOLISM | FOLLOW-UP | PREMENOPAUSAL WOMEN | HEALTHY POSTMENOPAUSAL WOMEN | AROMATASE INHIBITOR THERAPY | PLUS ZOLEDRONIC ACID | FAS LIGAND EXPRESSION
Journal Article
Osteoporosis International, ISSN 0937-941X, 11/2012, Volume 23, Issue 11, pp. 2567 - 2576
Aromatase inhibitors (AIs) are widely used in women with breast cancer, but they are known to increase bone loss and risk of fractures. Based on available... 
Medicine & Public Health | Gynecology | Orthopedics | Rheumatology | Breast cancer | Bone loss | Fracture risk | Bisphosphonates | Endocrinology | Aromatase inhibitors | RECEIVING ADJUVANT LETROZOLE | ATAC TRIAL | RANDOMIZED CLINICAL-TRIAL | ENDOCRINE THERAPY | FOLLOW-UP | VERTEBRAL FRACTURE | PREMENOPAUSAL WOMEN | VITAMIN-D DEFICIENCY | MINERAL DENSITY | ENDOCRINOLOGY & METABOLISM | PLUS ZOLEDRONIC ACID | Drug Administration Schedule | Humans | Middle Aged | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Antineoplastic Agents - therapeutic use | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Breast Neoplasms - drug therapy | Aromatase Inhibitors - adverse effects | Bone Density - drug effects | Osteoporotic Fractures - chemically induced | Antineoplastic Agents - adverse effects | Diphosphonates - therapeutic use | Female | Osteoporosis, Postmenopausal - chemically induced | Osteoporosis, Postmenopausal - physiopathology | Aged | Osteoporotic Fractures - physiopathology | Aromatase Inhibitors - therapeutic use | Dietary Supplements | Osteoporosis, Postmenopausal - prevention & control | Bones | Inhibitor drugs | Fractures | Risk factors | Drugs | Spine | Hormones | Hip | Post-menopause | International organizations | Osteoporosis | Aromatase | Risk assessment | Zoledronic acid | Bone mineral density | Skeleton
Journal Article
Maturitas, ISSN 0378-5122, 2016, Volume 95, pp. 65 - 71
Journal Article